 |
|
|
| |
PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-naïve HCV Genotype 1b-Infected Adults With or Without Ribavirin
|
| |
| |
Reported by Jules Levin
EASL - International Liver Congress, 9-13 April 2014, London, United Kingdom
Peter Ferenci1, Anders Nyberg2, Pedram Enayati 3, David Bernstein4, Yaacov Baruch5, Florin Alexandru Caruntu6, Vladimir Chulanov7, Ewa Janczewska8, Ziad Younes9, Rui T Marinho10, Giuliano Rizzardini11, Judit Gervain12, Ramon Planas13, Christophe Moreno14, Wangang Xie15, Christi ne Collins15, Daniel Cohen15, Marti n King15, Thomas Podsadecki15, K Rajender Reddy16
1Universitaetsklinik fuer Innere Medizin III, Vienna, Austria; 2Kaiser Permanente, San Diego, California, United States; 3California Liver Insti tute, Los Angeles, California, United States; 4North Shore University Hospital, Manhasset, New York, United States; 5Rambam Health Care Campus, Haifa, Israel;
6Nati onal Insti tute for Infecti ous Diseases "Prof. Dr. Matei Bals", Bucharest, Romania; 7Central Research Insti tute of Epidemiology, Moscow, Russia; 8ID Clinic, Mysowice, Poland; 9GastroOne, Germantown, Tennessee, United States; 10Centro Hospitalar Lisboa Norte, Lisboa, Portugal; 11Ospedale Luigi Sacco, Milano, Italy; 12Szent György Hospital, Szekesfehervár, Hungary; 13Hospital Germans Trías i Pujol, CIBERehd, Badalona, Spain; 14CUB Hopital Erasme, Universite Libre de Bruxelles, Belgium; 15AbbVie Inc., North Chicago, Illinois, United States; 16University of Pennsylvania, Philadelphia, Pennsylvania, United States
|
| |
|
|
|
|
|
